Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves muscle mass in patients.The ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion swallowable balloon Nik Ritza notes that an increasing number of people are now opting for an innovative, non-invasive treatment – the swallowable intragastric balloon (IGB).

Allurion cited prior studies demonstrating that its gastric balloon, combined with its Virtual Care Suite, has helped patients lose weight while maintaining or even increasing muscle mass.

The U.S. Patent and Trademark Office granted Patent No. 12,209,677, which pertains to advancements in Allurion's proprietary Balloon technology, particularly improving the precision of the valve ...

1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose ...

Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...

The U.S. Patent and Trademark Office granted Patent No. 12,209,677, which pertains to advancements in Allurion's proprietary Balloon technology, particularly improving the precision of the valve ...